<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939103</url>
  </required_header>
  <id_info>
    <org_study_id>luoyanxin</org_study_id>
    <nct_id>NCT04939103</nct_id>
  </id_info>
  <brief_title>EUS-FNA Versus MRI，CT，Enteroscope For The Prediction Of PCR After nCRT In Rectal Cancer</brief_title>
  <official_title>EUS-FNA Versus MRI,CT,Enteroscope for The Presiction of PCR Afer nCRT in Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colorectal cancer is one of the most malignancies worldwide.The dominant clinical research&#xD;
      strategy of LARC includes neoadjuvant chemoradiotherapy before radical surgery followed&#xD;
      combined with adjuvant treatment.Approximately 15% to 20% of the patients after nCRT can&#xD;
      achieve a pathologic complete response (pCR)---no residual tumor is reported at histology&#xD;
      after a standard resection.Some researchers suggest that those patients with pCR can be&#xD;
      spared the morbidities of surgery insteaded by nonoperative approach---watch-&#xD;
      and-wait(W&amp;W).However,neuther FDG-PET,nor MRI,nor CT,nor enteroscope can accurately determine&#xD;
      a pCR.&#xD;
&#xD;
      EUS-FNA has been an important technique for the diagnosis of rectal cancer for its high&#xD;
      accuracy and little harm.However,data on the EUS-FNA for the cytologic diagnosis of pCR in&#xD;
      rectal cancer is scarce.Our hypothesis is that adding EUS-FNA compared with enteroscope ,MR&#xD;
      and CT alone can improve the accuracy of predicting pCR after nCRT .Therefore,the aim of the&#xD;
      study is to assess the performance characteristics of EUS-FNA in this setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>7 Days</target_duration>
  <primary_outcome>
    <measure>the accuracy of predicting pCR after nCRT</measure>
    <time_frame>25/05/2021-25/05/2022</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">69</enrollment>
  <condition>EUS-FNA</condition>
  <condition>Rectal Cancer</condition>
  <condition>Pathological Complete Remission</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>those with the examination of EUS-FNA ,CT,MR,enteroscope</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-FNA</intervention_name>
    <description>transrectal ultrasound-guided core needle biopsy of rectal tumor</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all of the patients are from the sixth affiliated hospital of Sun Yet-sen University&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a new diagnosis of histologically confirmed rectal adenocarcinoma&#xD;
&#xD;
          -  tumor located below the peritoneum reflex&#xD;
&#xD;
          -  over 18 years old&#xD;
&#xD;
          -  T1-4,N0-2,M0 before nCRT&#xD;
&#xD;
          -  complete nCRT treatment&#xD;
&#xD;
          -  ASA&gt;III or ECOG&gt;1&#xD;
&#xD;
          -  informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multiple primary colorectal cancer&#xD;
&#xD;
          -  the history of malignant tumor,IBD,FAP&#xD;
&#xD;
          -  the history of chemoradiation treatment or resection of rectal tumor&#xD;
&#xD;
          -  actue abdomen disease requiring emergency surgery&#xD;
&#xD;
          -  not be able to tolerate surgery with severe organ dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>luo yanxin, MD,PHD</last_name>
    <role>Study Chair</role>
    <affiliation>the sixth affiliated hospital of Sun Yet-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>luo yanxin, MD,PHD</last_name>
    <phone>86-13826190263</phone>
    <email>luoyx25@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>huang yaoyi, BS</last_name>
    <phone>86-15986423743</phone>
    <email>401451200@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliate Hospital of Sun Yat-Sen University</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanxin Luo, PhD,MD</last_name>
      <phone>86-13826190263</phone>
      <email>luoyx25@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yaoyi Huang, BS</last_name>
      <phone>86-15986423743</phone>
      <email>linjx69@mail2.sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanxin Luo,MD</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>there is no plan to make individual participant data (IPD) available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

